ACE2 and COVID-19: Even though a human recombinant soluble ACE2 is in clinical trials to treat SARS-CoV-2 infection61, a catalytically inactive soluble ACE2 might be preferred from a safety perspective, as S-protein binding enhances ACE2’s carboxypeptidase activity62.